CISPLATIN NEUROPATHY - CLINICAL COURSE AND NEUROPHYSIOLOGICAL FINDINGS
CISPLATIN NEUROPATHY - CLINICAL COURSE AND NEUROPHYSIOLOGICAL FINDINGS
复制标题
DOI：
10.1007/bf00839140
复制
发表时间：
1992-04-01
影响因子：
6
通讯作者：
TONALI, P
中科院分区：
文献类型：
--
作者：
LOMONACO, M;MILONE, M;TONALI, P
16例患者给予顺铂（CDDP）40 mg/m2，第1-5天，每4周1次，共3个疗程（累积剂量600 mg/m2），于用药前、用药中、用药后1、3、6、9和12个月进行临床和神经生理学检查。9例患者中有4例在第二个疗程（累积剂量400 mg/m2）后首次出现多发性神经病症状。治疗后1个月，9例患者中有1例无症状，5例主诉症状，3例显示多发性神经病的临床和神经生理学体征。CDDP后3个月，所有患者均受到影响。CDDP治疗后6个月内观察到严重程度进展的临床和神经生理学体征。
Sixteen patients treated with cisplatin (CDDP) 40 mg/m2 on days 1-5 every 4 weeks for three courses (cumulative dose 600 mg/m2) were clinically and neurophysiologically tested before, during and 1, 3, 6, 9 and 12 months after CDDP administration. The first symptoms of polyneuropathy occurred in 4 of 9 patients after the second course (cumulative dose 400 mg/m2. One month after treatment 1 of 9 patients was asymptomatic, 5 complained of symptoms and 3 showed clinical and neurophysiological signs of polyneuropathy. Three months after CDDP all patients were affected. Clinical and neurophysiological signs of severity progression were noted up to 6 months after treatment with CDDP.